Dumont & Blake Investment Advisors LLC Purchases 205 Shares of Incyte Corporation $INCY

Dumont & Blake Investment Advisors LLC grew its position in Incyte Corporation (NASDAQ:INCY) by 0.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,791 shares of the biopharmaceutical company’s stock after buying an additional 205 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in Incyte were worth $1,756,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Czech National Bank boosted its holdings in shares of Incyte by 6.4% in the 2nd quarter. Czech National Bank now owns 39,271 shares of the biopharmaceutical company’s stock valued at $2,674,000 after buying an additional 2,378 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Incyte by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 213,947 shares of the biopharmaceutical company’s stock valued at $12,954,000 after buying an additional 1,419 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Incyte by 1.9% in the 1st quarter. Amalgamated Bank now owns 31,551 shares of the biopharmaceutical company’s stock valued at $1,910,000 after buying an additional 591 shares in the last quarter. OMNI 360 Wealth Inc. bought a new stake in shares of Incyte in the 2nd quarter valued at about $310,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Incyte by 26.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,467 shares of the biopharmaceutical company’s stock valued at $3,964,000 after purchasing an additional 13,523 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors.

Incyte Stock Performance

Shares of NASDAQ INCY opened at $87.57 on Friday. The company has a current ratio of 2.85, a quick ratio of 2.78 and a debt-to-equity ratio of 0.01. Incyte Corporation has a 12 month low of $53.56 and a 12 month high of $92.86. The company has a 50 day simple moving average of $85.20 and a two-hundred day simple moving average of $72.54. The stock has a market cap of $17.10 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 0.68 and a beta of 0.73.

Insider Buying and Selling

In other Incyte news, EVP Steven H. Stein sold 3,706 shares of Incyte stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $67.94, for a total transaction of $251,785.64. Following the completion of the sale, the executive vice president directly owned 102,886 shares in the company, valued at approximately $6,990,074.84. The trade was a 3.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 4,261 shares of company stock worth $298,482. Insiders own 17.80% of the company’s stock.

Analysts Set New Price Targets

INCY has been the subject of several research analyst reports. Wells Fargo & Company raised shares of Incyte from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $67.00 to $89.00 in a research report on Wednesday, August 6th. Guggenheim reaffirmed a “neutral” rating on shares of Incyte in a research report on Friday, September 19th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $60.00 price objective (up from $52.00) on shares of Incyte in a research report on Wednesday, July 30th. JPMorgan Chase & Co. increased their price objective on shares of Incyte from $73.00 to $89.00 and gave the company a “neutral” rating in a research report on Thursday, October 9th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $68.00 price objective (up from $62.00) on shares of Incyte in a research report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Incyte presently has a consensus rating of “Hold” and an average price target of $84.79.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.